Please login or register to print this page.

ARTICLE CONTRIBUTORS

Diagnostica Stago S.A.S

Clinical Articles, News & Views

Assay for apixaban plasma concentration

An assay for measuring the circulating blood concentration of the oral Factor Xa inhibitor apixaban is being developed in a joint research agreement between Bristol-Myers Squibb and Diagnostica Stago S.A.S, a privately held company that provides reference tests and instrumentation in haemostasis. No commercial assay is presently available to specifically measure apixaban plasma concentration. The terms of the agreement were not disclosed.

“Stago is pleased to have the opportunity to develop this test”, said Tristan Herve, Director of Pharmaceutical Development at Stago. “These oral Factor Xa inhibitors address an important unmet need for patients requiring anticoagulant therapy,” he added.

Stago has announced that they have already completed prototype development, and will be applying for health authority approval of the assay worldwide. The company retains 100% global development and commercialisation rights for the assay.

Published on: October 30, 2013

Members Area

Log in or Register now.

SEARCH THE SITE

RSS FEED

Subscribe to our RSS feed
home

GET EXCLUSIVE UPDATES

Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.

RECENT COMMENTS

    None Found

ENDORSED BY

  • ArrhythmiaAlliance
  • Stars
  • Anticoagulation Europe
  • Atrial Fibrillation Association
 

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.